Cataract TherapeuticsGlaucoma InsightsBranded vs GenericsCME ActivitiesGlaucoma Management

CataractClinical DiagnosisCorneaGlaucomaIOLOCTOcular AllergyOcular Surface DiseasePediatricsRefractiveRetinaTechnologyTherapeutic Cataract & RefractiveUnderstanding Antibiotic Resistance

All NewsBlogsCOVID-19

Expert InterviewsInsightsMedical World NewsPodcasts

Health Law & PolicyMoney MattersPersonal FinancePractice Management

Conference CoverageConference Listing

Digital EditionEurope Ophthalmology TimesModern Retina

CMEJob BoardSponsored Resources

eNewsletterPrint Subscription

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.

Spotlight

Cataract Therapeutics
Glaucoma Insights
Branded vs Generics
CME Activities
Glaucoma Management

ClinicalSee All >

Cataract
Clinical Diagnosis
Cornea
Glaucoma
IOL
OCT
Ocular Allergy
Ocular Surface Disease
Pediatrics
Refractive
Retina
Technology
Therapeutic Cataract & Refractive
Understanding Antibiotic Resistance

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences^™ and Ophthalmology Times. All rights reserved.

Phase III study eyes intravitreal therapy for exudative AMD

July 1, 2004

Anti-VEGF monoclonal antibody fragment improves vision, reduce fluorescein angiographic leakage